Prostate Cancer Treatment: Are We Irradiating Too Much?
"A new study questions the necessity of pelvic irradiation in prostate cancer, balancing toxicity and treatment efficacy."
Prostate cancer is a common diagnosis, and treatment strategies have evolved significantly over the years. Radiation therapy plays a crucial role, but the extent of radiation—specifically, whether to include the pelvic region alongside the prostate—is a topic of ongoing debate. The goal is always to eradicate the cancer effectively, but this must be carefully balanced against the potential for short- and long-term side effects that can significantly impact a patient's quality of life.
Traditionally, pelvic irradiation, which involves radiating the prostate and surrounding pelvic lymph nodes, has been used to target potential cancer spread. However, this broader approach exposes a larger area of the body to radiation, increasing the risk of toxicity. These toxicities can manifest as urinary problems, digestive issues, and other complications that can be distressing for patients.
A recent study presented at a medical conference has now brought this practice into question. Researchers investigated whether the benefits of pelvic irradiation outweigh the risks, particularly when compared to radiation focused solely on the prostate. The findings suggest that pelvic irradiation may not always be necessary and, in some cases, could lead to increased toxicity without a significant improvement in cancer control.
Treatment Choices and Long-Term Effects
NICE recommends considering pelvic radiotherapy for people with locally advanced prostate cancer when the risk of pelvic lymph node involvement is above 15% and treatment includes neoadjuvant hormonal therapy and radical radiotherapy. A 2025 cohort study reported that prostatectomy and radiotherapy were associated with significantly higher rates of long-term complications than no treatment, after accounting for age-related symptoms and disease. A separate analysis drew on 6,593 patients from six phase 3 randomized trials in the MARCAP Consortium to examine acute toxicity within three months of radiotherapy and late toxicity thereafter.
Radiotherapy Options and Late Effects
Radiotherapy may be used as an initial treatment for cancer confined to the prostate, particularly in lower-risk cases; the American Cancer Society says cure rates in these cases are similar to those with radical prostatectomy. A 2023 mini-review summarizes late side effects associated with standard and advanced radiotherapy techniques for localized prostate cancer. It also discusses SMART, a newer approach that may reduce late side effects and improve treatment effectiveness.
How Prostate Radiotherapy Evolved
A historical account describes prostate cancer as a locally aggressive disease recognized in the mid-to-late nineteenth century, followed by early twentieth-century radical surgeries that had relatively poor outcomes. External-beam radiotherapy came of age with high-energy linear accelerators in the 1960s–1980s, and its use increased dramatically after PSA testing was introduced in the 1980s. Radiation dose was constrained by side effects, particularly rectal effects, which limited prostate cancer control. A 2023 review also places diagnostic and treatment advances within the broader history of the past 60 years.
Is Pelvic Irradiation Really Necessary? Examining the Evidence
The study, conducted between April 2013 and November 2016, involved 189 patients treated for prostate cancer. All patients underwent intensity-modulated radiation therapy (IMRT) with daily image guidance to ensure precise targeting of the radiation. Researchers collected detailed clinical data, oncological parameters, and dosimetric data (radiation dose measurements) and closely monitored patients for urinary and digestive toxicities.
- Overall Toxicity Rates: 15.8% of patients experienced urinary toxicity of grade 2 or higher, while 8.9% experienced grade 2 digestive toxicity.
- Comparison of Irradiation Groups: There was no statistically significant difference in toxicity rates between the group that received pelvic irradiation and the group that received prostate-only irradiation (25.2% vs. 26.7%, p = 0.823).
- Prior TURP and Toxicity: Patients who had undergone a transurethral resection of the prostate (TURP) before radiation therapy showed a trend toward higher urinary toxicity (30% vs. 19%), although this difference was not statistically significant (p = 0.173).
- Gleason Score and Digestive Toxicity: A higher Gleason score (≥4) was associated with increased digestive toxicity (p = 0.045). The Gleason score is a measure of the aggressiveness of prostate cancer cells.
- Dosimetric Factors: No specific dosimetric parameter was identified as a risk factor for toxicity.
Technical Advances and Hypofractionation
A December 2025 article on reducing adverse effects in hypofractionated prostate radiotherapy describes technical advances that enabled hypofractionated and dose-escalated treatment schedules. The source highlights these schedules as a result of technical progress, but the provided summary does not report specific toxicity outcomes or quantify any reduction in adverse effects.
Limits in the Evidence on Pelvic Irradiation
The prospective PLATIN-1 trial used modern radiation techniques, but its authors said it was not powered to provide sufficient oncological outcome data. They cited its small patient number, non-randomized design, and some men receiving only short-term androgen-hormone therapy as limitations, and concluded that evidence for prophylactic pelvic-node irradiation remained lacking. Separately, a systematic review found few high-quality studies reporting 60-month toxicity rates after IMRT and called for longer follow-up and consistent toxicity reporting. A phase I/II study reported a mild-to-moderate burden of late gastrointestinal morbidity in patient-reported outcomes, while physician assessments showed a low prevalence of late GI morbidity scores.
Pelvic Nodes Versus Prostate-Only Radiation
A systematic review and meta-analysis found that whole pelvic radiotherapy (WPRT) significantly increased grade 2 or worse acute gastrointestinal toxicity compared with prostate-only radiotherapy: the relative risk was 1.75 in non-RP studies and 1.76 in RP studies. In the PIVOTAL phase 2 randomized trial, the pelvic lymph-node dose was approximately 7–10 Gy higher than in previous studies; its equivalent dose at 2 Gy per fraction was 55.4 Gy, compared with 48.4 Gy in RTOG and 46 Gy in Unicancer Genitourinary Group studies. In GETUG-01, event-free survival was higher but not significantly so in the low-risk subgroup receiving pelvic-node radiation: 77.2% versus 62.5% (P=.18).
The Path Forward: Balancing Cancer Control and Quality of Life
While the study's authors conclude that pelvic irradiation may not always increase toxicity, they emphasize the need for longer-term follow-up to validate these results. The quest to refine prostate cancer treatment is ongoing. As technology evolves and understanding of the disease deepens, treatments become more precise and tailored to individual patient needs.
Imaging During Treatment
A Harvard Health article describes a prostate cancer radiation technique that uses specialized medical imaging to let doctors visualize the cancer during treatment. The article says this approach can limit side effects from radiation therapy. The provided source summary does not name the technique or give a numerical estimate of its effects.
Early Effects as a Signal for Later Risk
A UCLA-led study reported that men receiving prostate cancer radiation who experience side effects early in treatment may face a higher risk of more serious long-term urinary and bowel health issues. The finding links early treatment effects with later problems, but the provided summary does not specify the size of the risk or establish that early symptoms cause them.
Patient Experiences and Late Toxicity
A qualitative study embedded in the ProtecT randomized controlled trial investigated the experiences of men receiving external-beam radiotherapy with neoadjuvant androgen deprivation therapy for localized prostate cancer. It purposively sampled 16 men to include a range of experiences. A separate registry study of more than 300 patients highlighted the real-world burden of late genitourinary toxicity after prostate radiotherapy and called for re-evaluating long-term toxicity in treatment planning and promoting integrated, multidisciplinary survivorship care.